• Quercetin Modulates Hippo Pathway to Protect Cataract Lenses

  2026-06-20

  This study demonstrates that quercetin alleviates cataract pathology by inhibiting the Hippo signaling pathway, leading to reduced lens opacity and enhanced survival of lens epithelial cells. These findings clarify a molecular mechanism for cataract protection and highlight targets for non-surgical intervention strategies.

• PPP2R2A Loss Sensitizes HGSOC to Chk1 Inhibition via Replica

  2026-06-19

  This study demonstrates that low PPP2R2A expression makes high-grade serous ovarian cancer (HGSOC) cells more sensitive to Chk1 inhibition by intensifying replication stress. These findings propose PPP2R2A as a predictive biomarker for Chk1 inhibitor response and a potential therapeutic target for overcoming PARP inhibitor resistance in ovarian cancer.

• CK2/ERK8 Inhibitor: Transforming LLPS Studies in Translation

  2026-06-19

  This thought-leadership article explores the mechanistic and strategic value of 2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid, a CK2 and ERK8 inhibitor, as a next-generation molecular tool for protein phase separation studies. By bridging kinase signaling and condensate biology, and contextualizing recent viral LLPS breakthroughs, we provide translational researchers with actionable guidance on experimental design, protocol parameters, and the evolving landscape of molecular discovery.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Applicati

  2026-06-18

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody addresses the need for sensitive, specific detection of goat IgG primaries in fluorescence-based immunodetection workflows. It is not suitable for use with non-goat primary antibodies or outside validated applications such as ICC/IF, IHC, flow cytometry, and ELISA.

• Homoharringtonine: Cytotoxic Alkaloid Workflows in Cancer &

  2026-06-18

  Homoharringtonine bridges oncology and virology with powerful, reproducible workflows for both leukemia research and SARS-CoV-2 antiviral studies. Learn stepwise protocols and troubleshooting strategies to maximize its cytotoxic and translational impact.

• Matrix Metalloproteinase-Responsive Hydrogel for Localized F

  2026-06-17

  This study introduces an injectable, matrix metalloproteinase-responsive nanoparticle hydrogel scaffold for sustained, localized delivery of RANKL inhibitors in fibrous dysplasia. The approach addresses the need for lesion-specific therapy while minimizing systemic exposure, demonstrating significant disease attenuation in a mouse model.

• Losartan as an Angiotensin II Receptor Antagonist in Vascula

  2026-06-17

  Losartan’s selective AT1 receptor blockade enables precise investigation of angiotensin II-driven vascular and renal mechanisms, making it invaluable for hypertension and podocyte injury studies. This guide distills experimental workflows, optimization strategies, and actionable troubleshooting tips for leveraging Losartan in advanced cardiovascular physiology research.

• FGF4-FGFR1 Axis Preserves Podocyte Function in Diabetic Kidn

  2026-06-16

  This study identifies podocyte-secreted FGF4 as a critical regulator of glomerular health in diabetic kidney disease (DKD), demonstrating that FGF4-FGFR1 signaling preserves podocyte survival and glomerular function via AMPK-FOXO1 pathways. The findings highlight a potential therapeutic target distinct from conventional angiotensin II receptor antagonists for DKD intervention.

• Mithramycin A in Cancer Biology: Mechanistic Depth and Resea

  2026-06-16

  Explore Mithramycin A, an anticancer antibiotic, through a deep dive into its selective DNA binding, polymerase inhibition, and emerging roles in leukemia and gene regulation research. This article offers advanced protocols and unique insights into assay optimization.

• Veratridine in Next-Gen Cardiac and Neuro Assays: Mechanism

  2026-06-15

  Explore how Veratridine, a potent voltage-gated sodium channel opener, is revolutionizing chamber-specific cardiac modeling and neurophysiology assays. This article provides a deep dive into its mechanism and unique role beyond standard sodium channel research.

• Bsa I (RNase-free): Practical Guide for Gene Cloning Workflo

  2026-06-15

  Bsa I (RNase-free) is designed for DNA cleavage in workflows where RNA integrity must be preserved, such as gene cloning and recombinant DNA technology. It is not suitable for diagnostic or clinical use, and is best reserved for sensitive molecular biology research requiring RNase-free conditions.

• Engineered KR-12 Peptides: Origami Strategies and Antimicrob

  2026-06-14

  The reference review details the structural engineering and application spectrum of KR-12, the smallest active fragment of human LL-37. Innovations include origami-inspired peptide modifications that enhance antimicrobial, anti-biofilm, and immunomodulatory functions, providing new directions for targeting drug-resistant pathogens.

• Fasudil (HA-1077) HCl: Applied ROCK Inhibition in Cancer Mod

  2026-06-13

  Fasudil (HA-1077) HCl from APExBIO enables precise Rho/ROCK pathway inhibition for cell proliferation, migration, and apoptosis studies in cancer and hematological models. This article provides optimized experimental workflows, troubleshooting strategies, and actionable insights for integrating Fasudil into advanced cell signaling research.

• Ginsenoside Rg1: Protocols and Troubleshooting in Neuroprote

  2026-06-12

  Ginsenoside Rg1, a Panax-derived triterpene saponin, is redefining experimental neuroprotection through precise modulation of neuroimmune pathways. This guide delivers protocol-driven insights, troubleshooting strategies, and actionable workflows for apoptosis and inflammation research, all anchored by recent advances in post-anesthesia neuroprotection.

• EDI3 Inhibition Reduces Tumor Growth in HER2+ Breast Cancer

  2026-06-12

  Keller et al. identified glycerophosphodiesterase EDI3 as a metabolic vulnerability in ER-HER2+ breast cancer cells that are resistant to HER2-targeted therapy. Their study demonstrates that targeting EDI3 impairs tumor cell viability and growth, suggesting a novel metabolic intervention point for overcoming therapeutic resistance.

8148 records 8/544 page Previous Next First page 上5页 678910 下5页 Last page